Skip to main content
Lasque Tiarc

Cutaneous T-cell lymphoma, the first results of the PROSPER study on mogalizumab presented

Vaseline 2 months ago

The real-life observational study aims to analyze the impact of treatment with the drug in patients suffering from the two most common subtypes of the disease.

Milan – The pharmaceutical company Kyowa Kirin presented i first real results of the PROSPER study at the 5th annual meeting of the World Cutaneous Lymphoma Congress in Pasadena, California, highlighting thepositive impact of mogamulizumab in patients with cutaneous T-cell lymphoma (CTCL)a rare, sometimes serious and life-threatening form of non-Hodgkin’s lymphoma.

CTCL is responsible for approximately 4% of all cases of non-Hodgkin’s lymphoma and up to 80% of all primary cutaneous lymphomas. In advanced stages of the disease, malignant T cells can spread to the lymphatic system, blood, bone marrow and internal organs. Therefore, it can have a profound impact on the quality of life related to the health and psychological well-being of patients.

Lo studio PROPER is a prospective observational study conducted in six countries in Europe, North America and the Middle East. Of this, Italy is the country with the most centers involved in the researchsix, in cities such as Ancona, Bologna, Florence, Milan and Rome (with 2 centres).

With follow-up up to 50 weeks after patients entered the study, The aim of the study is to analyze the impact of the drug in patients with mycosismgoid fungi (FM) and Sézary syndrome (SS), the two best known subtypes of CTCL. To analyze their symptoms and health-related quality of life (HRQoL), researchers collected information from patients and caregivers about their treatment experience.

In particular, The researchers analyzed symptom data collected from the first 20 patients included in the study, eight with mycosis Fungoides and twelve with Sézary syndrome during the first 16 weeks of treatment. Before starting treatment, patients reported a high burden of complaints on a numerical scale from 1 to 10, including itching of the skin (6.6), redness of the skin (6.2), peeling of the skin (5.9) and skin pain (4.0). In addition, more than half of patients reported having trouble sleeping “often” or “every night,” while 47% reported having trouble regulating body temperature “often” or “always.”

Four weeks after starting treatment, an improvement in all symptoms was reported. At week 16, symptom severity decreased significantly, with marked improvement observedredness of the skin (-2.9), followed by itching of the skin (-2.7), flaking of the skin (-2.5) e skin pain (-2.2). Strikingly, the percentage of patients who ‘often’ or ‘always’ reported sleep problems or difficulty regulating body temperature fell to less than 20%.

“We know that CTCL patients not only suffer from the stress of a cancer diagnosis, but that this stress is exacerbated by visual impairment and varying levels of discomfort and fatigue,” said one of the study’s lead investigators, Dr. Professor Julia Scarisbrick, from the University of Birmingham. “The PROSPER trial helps us better understand these critical issues and the impact mogamulizumab can have on patients’ symptoms and quality of life.”